Claims for Patent: 8,299,128

Summary for Patent: 8,299,128

Title:	Compositions comprising polymeric micelles for drug delivery
Abstract:	The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.
Inventor(s):	Sill; Kevin N. (Tampa, FL), Skaff; Habib (Tampa, FL), Breitenkamp; Kurt (San Diego, CA), Breitenkamp; Rebecca (San Diego, CA)
Assignee:	Intezyne Technologies, Inc. (Tampa, FL)
Application Number:	12/962,052
Patent Claims:	1. A composition comprising a drug-loaded micelle and a pharmaceutically acceptable carrier, adjuvant, or vehicle, wherein the micelle comprises a multiblock copolymer, wherein said micelle has a drug-loaded inner core, a non-crosslinked outer core, and a hydrophilic shell, wherein the multiblock copolymer is of formula I: ##STR01707## wherein: n is 10-2500; m is 1 to 1000; m' is 1 to 1000; R.sup.x is a natural or unnatural amino acid side-chain group that is capable of crosslinking; R.sup.y is a hydrophobic or ionic, natural or unnatural amino acid side-chain group; R.sup.1 is --Z(CH.sub.2CH.sub.2Y).sub.p(CH.sub.2).sub.tR.sup.3, wherein: Z is --O--, --S--, --C.ident.C--, or --CH.sub.2--; each Y is independently --O-- or --S--; p is 0-10; t is 0-10; and R.sup.3 is --N.sub.3, --CN, a mono-protected amine, a di-protected amine, a protected aldehyde, a protected hydroxyl, a protected carboxylic acid, a protected thiol, a 9-30 membered crown ether, or an optionally substituted group selected from aliphatic, a 5-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an 8-10 membered saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a detectable moiety; Q is a valence bond or a bivalent, saturated or unsaturated, straight or branched C.sub.1-12 alkylene chain, wherein 0-6 methylene units of Q are independently replaced by -Cy-, --O--, --NH--, --S--, --OC(O)--, --C(O)O--, --C(O)--, --SO--, --SO.sub.2--, --NHSO.sub.2--, --SO.sub.2NH--, --NHC(O)--, --C(O)NH--, --OC(O)NH--, or --NHC(O)O--, wherein: -Cy- is an optionally substituted 5-8 membered bivalent, saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R.sup.2a is a mono-protected amine, a di-protected amine, --N(R.sup.4).sub.2, --NR.sup.4C(O)R.sup.4, --NR.sup.4C(O)N(R.sup.4).sub.2, --NR.sup.4C(O)OR.sup.4, or --NR.sup.4SO.sub.2R.sup.4; and each R.sup.4 is independently an optionally substituted group selected from hydrogen, aliphatic, a 5-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an 8-10 membered saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a detectable moiety, or: two R.sup.4 on the same nitrogen atom are taken together with said nitrogen atom to form an optionally substituted 4-7 membered saturated, partially unsaturated, or aryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 2. The composition according to claim 1, wherein the amino acid is aspartic acid or glutamic acid. 3. The composition according to claim 1, wherein the amino acid is histidine. 4. The composition according to claim 1, wherein said micelle is a mixed micelle. 5. The composition according to claim 1, wherein R.sup.1 is ##STR01708## 6. The composition according to claim 1, wherein R.sup.2a is selected from the group consisting of: ##STR01709## 7. The composition according to claim 1, wherein R.sup.y is a hydrophobic amino acid side-chain selected from a phenylalanine side-chain, alanine side-chain, benzyl or alkyl glutamate side chain, a benzyl or alkyl aspartate side chain, or leucine side-chain, and optionally one or more of tyrosine side-chain, serine side-chain, threonine side-chain, glutamic acid, or aspartic acid such that the overall poly(amino acid) block is hydrophobic. 8. The composition according to claim 7, wherein R.sup.y is a hydrophobic amino acid side-chain selected from a mixture of phenylalanine and tyrosine or a mixture of leucine and tyrosine, such that the overall poly(amino acid) block is hydrophobic. 9. The composition according to claim 1, wherein: n is about 200 to about 300; m is 5-25; m' is 10-50; and R.sup.2a is --NHC(O)CH.sub.3. 10. The composition according to claim 1, wherein the micelle encapsulates a hydrophobic chemotherapeutic drug selected from Abarelix, Aldesleukin, Aldesleukin, Alemtuzumab, Alitretinoin, Allopurinol, Altretamine, Amifostine, Anastrozole, Arsenic trioxide, Asparaginase, Azacitidine, BCG Live, Bevacuzimab, Avastin, Fluorouracil, Bexarotene, Bleomycin, Bortezomib, Busulfan, Calusterone, Capecitabine, Camptothecin, Carboplatin, Carmustine, Celecoxib, Cetuximab, Chlorambucil, Cisplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Dactinomycin, Darbepoetin alfa, Daunorubicin, Denileukin, Dexrazoxane, Docetaxel, Doxorubicin, Doxorubicin hydrochloride, Dromostanolone Propionate, Epirubicin, Epoetin alfa, Erlotinib, Estramustine, Etoposide Phosphate, Etoposide, Exemestane, Filgrastim, floxuridine fludarabine, Fulvestrant, Gefitinib, Gemcitabine, Gemtuzumab, Goserelin Acetate, Histrelin acetate, Hydroxyurea, Ibritumomab, Idarubicin, Ifosfamide, Imatinib Mesylate, Interferon alfa-2a, Interferon alfa-2b, Irinotecan, Lenalidomide, Letrozole, Leucovorin, Leuprolide Acetate, Levamisole, Lomustine, Megestrol Acetate, Melphalan, Mercaptopurine, 6-MP, Mesna, Methotrexate, Methoxsalen, Mitomycin C, Mitotane, Mitoxantrone, Nandrolone, Nelarabine, Nofetumomab, Oprelvekin, Oxaliplatin, Paclitaxel, Palifermin, Pamidronate, Pegademase, Pegaspargase, Pegfilgrastim, Pemetrexed Disodium, Pentostatin, Pipobroman, Plicamycin, Porfimer Sodium, Procarbazine, Quinacrine, Rasburicase, Rituximab, Sargramostim, Sorafenib, Streptozocin, Sunitinib Maleate, Talc, Tamoxifen, Temozolomide, Teniposide, VM-26, Testolactone, Thioguanine, 6-TG, Thiotepa, Topotecan, Toremifene, Tositumomab, Trastuzumab, Tretinoin, ATRA, Uracil Mustard, Valrubicin, Vinblastine, Vincristine, Vinorelbine, Zoledronate, or Zoledronic acid. 11. A method for treating a cancer in a patient comprising administering to said patient the composition according to claim 10. 12. The method according to claim 11, wherein the cancer is selected from breast, ovary, cervix, prostate, testis, genitourinary tract, esophagus, larynx, glioblastoma, neuroblastoma, stomach, skin, keratoacanthoma, lung, epidermoid carcinoma, large cell carcinoma, small cell carcinoma, lung adenocarcinoma, bone, colon, adenoma, pancreas, adenocarcinoma, thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma, bladder carcinoma, liver carcinoma and biliary passages, kidney carcinoma, myeloid disorders, lymphoid disorders, Hodgkin's, hairy cells, buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx, small intestine, colon-rectum, large intestine, rectum, brain and central nervous system, and leukemia, wherein said micelle encapsulates a chemotherapeutic agent suitable for treating said cancer. 13. The composition according to claim 10, wherein the hydrophobic chemotherapeutic drug is Doxorubicin or Doxorubicin hydrochloride. 14. The composition according to claim 10, wherein the hydrophobic chemotherapeutic drug is Gemcitabine. 15. The composition according to claim 10, wherein the hydrophobic chemotherapeutic drug is Letrozole. 16. The composition according to claim 1, wherein the composition is formulated for parenteral administration to a patient. 17. The composition according to claim 16, wherein the composition is formulated for intravenous administration to a patient. 18. The composition according to claim 1, wherein the composition is formulated for oral administration to a patient. 19. The composition according to claim 18, wherein the composition is formulated for oral administration to a patient as a capsule, a tablet, an aqueous suspension or a solution. 20. The composition according to claim 1, wherein the micelle encapsulates a drug for treating Alzheimer's disease, Parkinson's disease, multiple sclerosis, asthma, schizophrenia, inflammation, an autoimmune disorder, cardiovascular disease, liver disease, a viral disorder, a blood disorder, or an immunodeficiency disorder. 21. The composition according to claim 20, wherein the micelle encapsulates a drug selected from Aricept.RTM., Excelon.RTM., L-DOPA/carbidopa, entacapone, ropinrole, pramipexole, bromocriptine, pergolide, trihexephendyl, amantadine, beta interferon, Copaxone.RTM., mitoxantrone, a steroid, albuterol, Singulair.RTM., zyprexa, risperdal, seroquel, haloperidol, a corticosteroid, a TNF blocker, IL-1 RA, azathioprine, cyclophosphamide, sulfasalazine, cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, interferons, cyclophophamide, azathioprine, sulfasalazine, an acetylcholinesterase inhibitor, an MAO inhibitor, an interferon, an anti-convulsant, an ion channel blocker, riluzole, a beta-blocker, an ACE inhibitor, a diuretic, a nitrate, a calcium channel blocker, a statin, cholestyramine, an anti-viral agent, an anti-leukemic agent, a growth factor, or gamma globulin. 22. The composition according to claim 18, wherein the micelle encapsulates a drug for treating Alzheimer's disease, Parkinson's disease, multiple sclerosis, asthma, schizophrenia, inflammation, an autoimmune disorder, cardiovascular disease, liver disease, a viral disorder, a blood disorder, or an immunodeficiency disorder. 23. The composition according to claim 22, wherein the micelle encapsulates a drug selected from Aricept.RTM., Excelon.RTM., L-DOPA/carbidopa, entacapone, ropinrole, pramipexole, bromocriptine, pergolide, trihexephendyl, amantadine, beta interferon, Copaxone.RTM., mitoxantrone, a steroid, albuterol, Singulair.RTM., zyprexa, risperdal, seroquel, haloperidol, a corticosteroid, a TNF blocker, IL-1 RA, azathioprine, cyclophosphamide, sulfasalazine, cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, interferons, cyclophophamide, azathioprine, sulfasalazine, an acetylcholinesterase inhibitor, an MAO inhibitor, an interferon, an anti-convulsant, an ion channel blocker, riluzole, a beta-blocker, an ACE inhibitor, a diuretic, a nitrate, a calcium channel blocker, a statin, cholestyramine, an anti-viral agent, an anti-leukemic agent, a growth factor, or gamma globulin.

Details for Patent 8,299,128

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2025-04-01
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2025-04-01
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2025-04-01
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2025-04-01
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2025-04-01